Forging Ahead with Resolve and Continuity: Northland Biotech Successfully Hosts 2026 Investor Day

To build an efficient communication bridge with investors and further convey the company’s core values and development strategy, Beijing Northland Biotechnology Co., Ltd. (Stock Code: 920047, hereinafter referred to as “Northland”) held its 2026 Investor Reception Day on June 10, 2026, at the POSCO Center in Wangjing, Beijing. Mr. Xu Songshan, Chairman of the Board and General Manager, attended the event together with the core management team. They engaged in comprehensive and in-depth discussions with onsite investors on topics including the clinical value, commercialization layout, R&D planning, National Reimbursement Drug List (NRDL) application, and capacity building for Sedominigene Injection (brand name: Huasuoling®), the world’s first therapeutic naked plasmid gene therapy drug. The event attracted participation from over 60 institutional and individual investors, including China Securities Co., Ltd., Harvest Fund Management Co., Ltd., Guotai Haitong Securities Co., Ltd., and CITIC Securities Co., Ltd., demonstrating strong market attention toward the company.

This event focused on the R&D achievements and future prospects of Sedominji Injection. Nie Liya, Director and Deputy General Manager of the company, provided a detailed review of the R&D journey, technological advancement, and originality of Sedominji Injection, as well as the various policy supports granted by national and local authorities for the innovative drug sector. Han Chengquan, Director and Deputy General Manager, shared the clinical trial results of Sedominji Injection and introduced the post-marketing research plan for the product. He elaborated on the scientific rationale and convenience of the administration method, highlighting the clinical advantages of the product. Xu Huadong, Sales Director, outlined strategies regarding sales, market layout, team building, target market positioning, and compliant operations, clarifying the implementation path and phased objectives for the commercialization of the product. Wang Yongjiang, General Manager of the subsidiary, provided a detailed introduction to the production assurance capabilities of the contracted manufacturing partner, Yaohai Bio, and the completion and commissioning plans for the self-built factory, demonstrating the alignment between production line capacity and market demand.

Mr. Xu Songshan, Chairman of the Board and General Manager of the Company, delivered the concluding remarks. He pointed out that the approval of Sedomingji Injection marks a significant milestone in Northland’s journey of innovative development, representing a major achievement from the company’s more than two decades of deep commitment to the field of gene therapy. As an original Chinese gene therapy drug, Sedomingji Injection will provide a novel therapeutic option for patients with critical limb ischemia (CLI) who are unsuitable for revascularization procedures or have experienced poor surgical outcomes—often referred to as “no-option” patients. It fills a clinical treatment gap in this area, carrying substantial clinical value and industry-leading significance. The company will continue to uphold its core philosophy of “Innovation-Driven, Patient-First,” steadily advance product commercialization, continuously increase investment in R&D innovation, optimize production capacity layout, and actively promote the inclusion of innovative drugs in the national medical insurance program. By doing so, it aims to reward investors’ trust through stable operations and contribute to the high-quality development of China’s biopharmaceutical industry through genuine innovation.

The successful holding of this Investor Reception Day fully demonstrated the Company’s robust capabilities and confidence in its deep commitment to the gene therapy sector, effectively enhancing capital market understanding of its core products, strategic plans, and growth potential. Moving forward, the Company will continue to uphold the principles of openness and transparency, strengthen regular communication with investors, share updates on corporate developments, and work hand-in-hand with investors for mutual benefit, jointly contributing to the Company’s long-term and stable growth.

Submit Your Startup Story, Share Great Business Ideas. Click Here to Explore New Entrepreneurial Opportunities Together!